IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v37y2019i4d10.1007_s40273-019-00783-8.html
   My bibliography  Save this article

Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders

Author

Listed:
  • Tara A. Lavelle

    (Tufts Medical Center
    Tufts University School of Medicine)

  • Milton C. Weinstein

    (Harvard T.H. Chan School of Public Health)

  • Joseph P. Newhouse

    (Harvard Medical School
    Harvard T.H. Chan School of Public Health
    Harvard Kennedy School
    National Bureau of Economic Research)

  • Kerim Munir

    (Boston Children’s Hospital
    Harvard Medical School)

  • Karen A. Kuhlthau

    (Harvard Medical School
    Massachusetts General Hospital)

  • Lisa A. Prosser

    (University of Michigan)

Abstract

Background Few studies have used preference-based quality-of-life outcomes to assess how autism spectrum disorders (ASDs) affect children and parents, and none have examined variation by ASD severity. Objective Our objective was to derive parent valuations of child and parent health associated with varying ASD severity levels. Methods Parents of children aged 3–17 years with and without ASD were selected from a nationally representative research panel to complete a survey. We asked parents time trade-off (TTO) questions to value their own and their child’s current health. Parents of children with ASD were asked to report the severity of their child’s core ASD symptoms. We calculated utility values from each TTO amount, and used a two-part regression model to estimate the change in parent-reported child health utility, as well as parent health utility, associated with ASD diagnosis and increasing symptom severity, controlling for respondent and child characteristics. Results Sixty-nine percent of parents responded (final sample size was 135 in the ASD group and 120 in the comparison group). In adjusted analyses, there was a 0.12 (95% confidence interval [CI] 0.03–0.21) decrease in the parent-reported health utility of children with ASD, a 15% decrease from the mean health utility of children without ASD. On average, having a child with ASD was not significantly associated with a decrease in parent health utility, but there was a 0.14 (95% CI 0.01–0.26) reduction in health utility among parents of children with severe ASD, a 15% decrease from the comparison group mean. Conclusions Overall, ASD had a significant impact on parent-reported child health utility, and the health utility of parents of children with severe ASD.

Suggested Citation

  • Tara A. Lavelle & Milton C. Weinstein & Joseph P. Newhouse & Kerim Munir & Karen A. Kuhlthau & Lisa A. Prosser, 2019. "Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders," PharmacoEconomics, Springer, vol. 37(4), pages 541-551, April.
    • Handle: RePEc:spr:pharme:v:37:y:2019:i:4:d:10.1007_s40273-019-00783-8
    DOI: 10.1007/s40273-019-00783-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-019-00783-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-019-00783-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Dolan, Paul & Roberts, Jennifer, 2002. "To what extent can we explain time trade-off values from other information about respondents?," Social Science & Medicine, Elsevier, vol. 54(6), pages 919-929, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Zhihao Yang & Kim Rand & Elly Stolk & Jan Busschbach & Nan Luo, 2024. "Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(7), pages 1087-1094, September.
    2. Lisa A. Prosser & Eve Wittenberg, 2019. "Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness," PharmacoEconomics, Springer, vol. 37(4), pages 447-450, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kharroubi, Samer & Brazier, John E. & O'Hagan, Anthony, 2007. "Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method," Social Science & Medicine, Elsevier, vol. 64(6), pages 1242-1252, March.
    2. Agata Łaszewska & Ayesha Sajjad & Jan Busschbach & Judit Simon & Leona Hakkaart-van Roijen, 2022. "Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments," PharmacoEconomics, Springer, vol. 40(12), pages 1221-1234, December.
    3. Marisa Santos & Monica A. C. T. Cintra & Andrea L. Monteiro & Braulio Santos & Fernando Gusmão-filho & Mônica Viegas Andrade & Kenya Noronha & Luciane N. Cruz & Suzi Camey & Bernardo Tura & Paul Kin, 2016. "Brazilian Valuation of EQ-5D-3L Health States," Medical Decision Making, , vol. 36(2), pages 253-263, February.
    4. Katharine S. Gries & Dean A. Regier & Scott D. Ramsey & Donald L. Patrick, 2017. "Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 375-384, June.
    5. Asrul Akmal Shafie & Annushiah Vasan Thakumar, 2020. "Multiplicative modelling of EQ-5D-3L TTO and VAS values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1411-1420, December.
    6. Floortje Nooten & Jan Busschbach & Michel Agthoven & Job Exel & Werner Brouwer, 2018. "What should we know about the person behind a TTO?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1207-1211, December.
    7. Edward J. D. Webb & Paul Kind & David Meads & Adam Martin, 2021. "Does a health crisis change how we value health?," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2547-2560, September.
    8. Gaurav Jyani & Zhihao Yang & Atul Sharma & Aarti Goyal & Elly Stolk & Fredrick Dermawan Purba & Sandeep Grover & Manmeet Kaur & Shankar Prinja, 2023. "Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study," Medical Decision Making, , vol. 43(6), pages 692-703, August.
    9. Sahar Al Shabasy & Fatima Al Sayah & Maggie Abbassi & Samar Farid, 2022. "Determinants of Health Preferences Using Data from the Egyptian EQ-5D-5L Valuation Study," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 15(5), pages 589-598, September.
    10. Stefan A. Lipman & Brigitte A. B. Essers & Aureliano P. Finch & Ayesha Sajjad & Peep F. M. Stalmeier & Bram Roudijk, 2022. "In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives," PharmacoEconomics, Springer, vol. 40(2), pages 181-192, December.
    11. Donna Rowen & Brendan Mulhern & Sube Banerjee & Rhian Tait & Caroline Watchurst & Sarah C. Smith & Tracey A. Young & Martin Knapp & John E. Brazier, 2015. "Comparison of General Population, Patient, and Carer Utility Values for Dementia Health States," Medical Decision Making, , vol. 35(1), pages 68-80, January.
    12. Arthur Attema & Werner Brouwer, 2012. "The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 491-500, August.
    13. F. E. van Nooten & X. Koolman & W. B. F. Brouwer, 2009. "The influence of subjective life expectancy on health state valuations using a 10 year TTO," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 549-558, May.
    14. Rodríguez-Míguez, E. & Abellán-Perpiñán, J.M. & Alvarez, X.C. & González, X.M. & Sampayo, A.R., 2016. "The DEP-6D, a new preference-based measure to assess health states of dependency," Social Science & Medicine, Elsevier, vol. 153(C), pages 210-219.
    15. Peep F. M. Stalmeier & Jan J. V. Busschbach & Leida M. Lamers & Paul F. M. Krabbe, 2005. "The gap effect: discontinuities of preferences around dead," Health Economics, John Wiley & Sons, Ltd., vol. 14(7), pages 679-685, July.
    16. R. Hoorn & A. Donders & M. Oppe & P. Stalmeier, 2014. "The Better than Dead Method: Feasibility and Interpretation of a Valuation Study," PharmacoEconomics, Springer, vol. 32(8), pages 789-799, August.
    17. Lidia Engel & Nick Bansback & Stirling Bryan & Mary M. Doyle-Waters & David G. T. Whitehurst, 2016. "Exclusion Criteria in National Health State Valuation Studies," Medical Decision Making, , vol. 36(7), pages 798-810, October.
    18. Nicolas A. Menzies & Joshua A. Salomon, 2011. "Non‐monotonicity in the episodic random utility model," Health Economics, John Wiley & Sons, Ltd., vol. 20(12), pages 1523-1531, December.
    19. Richard Norman & Rebecca Mercieca‐Bebber & Donna Rowen & John E. Brazier & David Cella & A. Simon Pickard & Deborah J. Street & Rosalie Viney & Dennis Revicki & Madeleine T. King & On behalf of the Eu, 2019. "U.K. utility weights for the EORTC QLU‐C10D," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1385-1401, December.
    20. David Feeny, 2013. "Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions," Medical Decision Making, , vol. 33(3), pages 316-319, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:4:d:10.1007_s40273-019-00783-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.